顺铂
贝伐单抗
血管内皮生长因子
卵巢
卵巢癌
血管生成
癌症研究
组织微阵列
体内
癌症
医学
细胞培养
卵巢癌
血管内皮生长因子A
透明细胞癌
免疫组织化学
生物
化疗
病理
内科学
血管内皮生长因子受体
生物技术
遗传学
作者
Seiji Mabuchi,Chiaki Kawase,Deborah A. Altomare,Ken‐ichirou Morishige,Masami Hayashi,Kenjiro Sawada,Kimihiko Ito,Yoshito Terai,Shin Nishio,Andres J. Klein‐Szanto,Robert A. Burger,Masahide Ohmichi,Joseph R. Testa,Tadashi Kimura
出处
期刊:Molecular Cancer Therapeutics
[American Association for Cancer Research]
日期:2010-08-01
卷期号:9 (8): 2411-2422
被引量:68
标识
DOI:10.1158/1535-7163.mct-10-0169
摘要
Abstract This study examines the role of vascular endothelial growth factor (VEGF) as a therapeutic target in clear cell carcinoma (CCC) of the ovary, which has been regarded as a chemoresistant histologic subtype. Immunohistochemical analysis using tissue microarrays of 98 primary ovarian cancers revealed that VEGF was strongly expressed both in early-stage and advanced-stage CCC of the ovary. In early-stage CCCs, patients who had tumors with high levels of VEGF had significantly shorter survival than those with low levels of VEGF. In vitro experiments revealed that VEGF expression was significantly higher in cisplatin-refractory human CCC cells (RMG1-CR and KOC7C-CR), compared with the respective parental cells (RMG1 and KOC7C) in the presence of cisplatin. In vivo treatment with bevacizumab markedly inhibited the growth of both parental CCC cell–derived (RMG1 and KOC7C) and cisplatin-refractory CCC cell–derived (RMG1-CR and KOC7C-CR) tumors as a result of inhibition of tumor angiogenesis. The results of the current study indicate that VEGF is frequently expressed and can be a promising therapeutic target in the management of CCC. Bevacizumab may be efficacious not only as a first-line treatment but also as a second-line treatment of recurrent disease in patients previously treated with cisplatin. Mol Cancer Ther; 9(8); 2411–22. ©2010 AACR.
科研通智能强力驱动
Strongly Powered by AbleSci AI